Stockreport

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026...

Palvella Therapeutics, Inc.  (PVLA) 
PDF WAYNE, Pa., April 20, 2026 (GLOBE NEWSWIRE) Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused o [Read more]